Some aspects of preventing coronary heart disease

Angiology

Volumn 63, Issue 1, 2012, Pages 17-23

  Agewall, Stefan ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

coronary heart disease; primary prevention

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; LINOLENIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; OMEGA 3 FATTY ACID;

ABDOMINAL OBESITY; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; DIABETES MELLITUS; ETHNIC GROUP; FRUIT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMOBILIZATION; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; PSORIASIS; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SOCIAL PSYCHOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; VEGETABLE; WAIST CIRCUMFERENCE;

BLOOD PRESSURE; CHOLESTEROL; CORONARY DISEASE; HEALTH BEHAVIOR; HUMANS; PRIMARY PREVENTION; RISK FACTORS;

EID: 82955187933     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319711407060     Document Type: Article

References (58)

1. Daviglus ML, Stamler J, Pirzada A, et al. Favorable cardiovascular risk profile in young women and long-term risk of cardiovascular and all-cause mortality. JAMA. 2004 ; 292 (13). 1588-1592 (Pubitemid 39314965)
2. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004 ; 364 (9438). 937-952 (Pubitemid 39208455)
3. Bartecchi C, MacKenzie TD, Schrier RW. The human costs of tobacco use (1). N Engl J Med. 1994 ; 330 (13). 907-912
4. MacKenzie T, Bartecchi CE, Schrier RW. The human costs of tobacco use (2). N Engl J Med. 1994 ; 330 (14). 975-980
5. The Health Benefits of Smoking Cessation. Washington, DC: US Department of Health and Human Services ; 1990 :
6. Lam T, He Y. Passive smoking and coronary heart disease: a brief review. Clin Exp Pharmacol Physiol. 1997 ; 24 (12). 993-996 (Pubitemid 27494317)
7. McEwen A, Hajek P, McRobbic H, West R Manual of Smoking Cessation. Oxford: Blackwell Publishers ; 2006 :
8. Manson J, Tosteson H, Ridker PM, et al. The primary prevention of myocardial infarction. N Engl J Med. 1992 ; 326 (21). 1406-1416
9. Barth J, Bengel J Contributions Toward Evidence-based Psychocardiology-A Systematic Review of the Literature. Jordan J Barde B Zeiher AM, ed. Washington, DC: American Psychological Association ; 2007: 83-105.
10. A clinical practice guideline for treating tobacco use and dependence: 2008 update: a U.S. Public Health Service report. Am J Prev Med. 2008 ; 35 (2). 158-176
11. Black JH 3rd. Evidence base and strategies for successful smoking cessation. J Vasc Surg. 2010 ; 51 (6). 1529-1537
12. Meyers DG, Neuberger JS, He J. Cardiovascular effect of bans on smoking in public places: a systematic review and meta-analysis. J Am Coll Cardiol. 2009 ; 54 (14). 1249-1255
13. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med. 2000 ; 343 (1). 16-22 (Pubitemid 30447987)
14. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999 ; 99 (6). 779-785 (Pubitemid 29083018)
15. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSIPrevenzione trial Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999 ; 354 (9177). 447-455
16. Kris-Etherton PM, Harris WS, Appel LJ. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002 ; 106 (21). 2747-2757 (Pubitemid 35364932)
17. Geleijnse JM, Giltay EJ, Schouten EG, et al. Effect of low doses of n-3 fatty acids on cardiovascular diseases in 4,837 post-myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. Am Heart J. 2010 ; 159 (4). 539-546
18. US Dept of Health and Human Services and US Dept of Agriculture. 6 th ed.Washington, DC:US Government Printing Office; 2005. Washington, DC: US Government Printing Office ; 2005 :
19. Micha R, Wallace SK, Mozaffarian D. Red and processed meat consumption and risk of incident coronary heart disease, stroke, and diabetes mellitus: a systematic review and meta-analysis. Circulation. 2010 ; 121 (21). 2271-2283
20. Guiraud V, Amor MB, Mas JL, Touzé E. Triggers of ischemic stroke: a systematic review. Stroke. 2010 ; 41 (11). 2669-2677
21. Rehm J, Taylor B, Mohapatra S, et al. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis. Drug Alcohol Rev. 2010 ; 29 (4). 437-445
22. Paffenbarger RS, Hyde RT, Wing AL, Hsieh CC. Physical activity, all-cause mortality, and longevity of college alumni. N Engl J Med. 1986 ; 314 (10). 605-613 (Pubitemid 16132724)
23. Oldridge NB, Guyatt GH, Fischer ME, Rimm AA. Cardiac rehabilitation after myocardial infarction: combined experience of randomized clinical trials. JAMA. 1988 ; 260 (7). 945-950
24. Graham I, Atar D, Borch-Johnsen K, et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007 ; 14 (suppl 2). S1 - S113
25. Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009 ; 373 (9669). 1083-1096
26. Preventing and Managing the Global Epidemic: Report of a WHO Consultation. Geneva: World Health Organization ; 2000 :
27. Despres J, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoprotein, and cardiovascular disease. Arteriosclerosis. 1990 ; 10 (4). 497-511 (Pubitemid 20220572)
28. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. Obes Res. 1998 ; 6 (suppl 2). 51S - 209S
29. Rejeski W, Brawley LR, Ambrosius WT, et al. Older adults with chronic disease: benefits of group-mediated counseling in the promotion of physically active lifestyles. Health Physiol. 2003 ; 22 (4). 414-423 (Pubitemid 36944580)
30. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 ; 120 (16). 1640-1645
31. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000 ; 160 (14). 2101-2107 (Pubitemid 30482715)
32. Blumenthal J, Sherwood A, Babyak MA, et al. Effects of exercise and stress management training on markers of cardiovascular risk in patients with ischemic heart disease: a randomized controlled trial. JAMA. 2005 ; 293 (13). 1626-1634 (Pubitemid 40471793)
33. Thombs BD, de Jonge P, Coyne JC, et al. Depression screening and patient outcomes in cardiovascular care: a systematic review. JAMA. 2008 ; 300 (18). 2161-2171
34. Whooley MA, de Jonge P, Vittinghoff E, et al. Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA. 2008 ; 300 (20). 2379-2388
35. Chida Y, Steptoe A. The association of anger and hostility with future coronary heart disease: a meta-analytic review of prospective evidence. J Am Coll Cardiol. 2009 ; 53 (11). 936-946
36. Linden W, Stossel C, Maurice J. Psychosocial interventions for patients with coronary artery disease: a meta-analysis. Arch Intern Med. 1996 ; 156 (7). 745-752 (Pubitemid 26108196)
37. Dusseldorp E, van Elderen T, Maes S, Meulman J, Kraaij V. A meta-analysis of psychoeduational programs for coronary heart disease patients. Health Psychol. 1999 ; 18 (5). 506-519 (Pubitemid 29468523)
38. Mancia G, De Backer G, Dominiczak A, et al. The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007 ; 28 (12). 1462-1536
39. Principal results of the Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS). Hypertens Res. 2008 ; 31 (12). 2115-2127
40. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood pressure control in type 2 diabetes mellitus. N Engl J Med. 2010 ; 362 (17). 1575-1585
41. Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?. Ann Intern Med. 2006 ; 144 (12). 884-893 (Pubitemid 46768128)
42. Sleight P, Redon J, Verdecchia P, et al;. on behalf of the ONTARGET Investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial Study. J Hypertens. 2009 ; 27 (7). 1360-1369
43. Farnett L, Muldrow CD, Linn WD, Lucey CR, Tuley MR. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous?. JAMA. 1991 ; 265 (4). 489-495
44. Fagerberg B, Wikstrand J, Berglund G, Samuelsson O, Agewall S. Mortality rates in treated hypertensive men with additional risk factors are high but can be reduced: a randomized intervention study. Am J Hypertens. 1998 ; 11 (1 Pt 1). 14-22 (Pubitemid 28083147)
45. Verschuren WMM, Jacobs DR, Bloemberg BPM, et al. Serum total cholesterol and long term coronary heart disease mortality in different cultures: twenty five year follow up of the Seven Country Study. JAMA. 1995 ; 274 (2). 131-136
46. The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. Circulation. 1990 ; 81 (5). 1721-1733
47. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 ; 366 (9493). 1267-1278
48. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005 ; 294 (3). 326-333 (Pubitemid 41043776)
49. Denke MA. Dietary fats, fatty acids, and their effects on lipoproteins. Curr Atheroscler Rep. 2006 ; 8 (6). 466-471 (Pubitemid 44697799)
50. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 ; 333 (20). 1301-1307
51. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of FCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998 ; 279 (20). 1615-1622 (Pubitemid 28248586)
52. Rydén L, Standl E, Bartnik M, et al. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007 ; 28 (1). 88-136 (Pubitemid 46137814)
53. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 ; 346 (6). 393-403
54. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998 ; 352 (9131). 854-865
55. Mattila TK, de Boer A. Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus. Drugs. 2010 ; 70 (17). 2229-2245
56. Dhawan SS, Quyyumi AA. Rheumatoid arthritis and cardiovascular disease. Curr Astheroscler Rep. 2008 ; 10 (2). 128-133 (Pubitemid 351486147)
57. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005 ; 352 (16). 1685-1695
58. Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 ; 359 (21). 2195-2207